Jason Duquette

发表

Discovery of potent and specific CXCR3 antagonists.

B. Lemon, S. Miao, T. Sullivan, 2012, Bioorganic & medicinal chemistry letters.

Discovery of AMG 925, a FLT3 and CDK4 dual kinase inhibitor with preferential affinity for the activated state of FLT3.

K. Pattabiraman, Zhulun Wang, C. Quéva, 2014, Journal of medicinal chemistry.

Discovery and in Vivo Evaluation of the Potent and Selective PI3Kδ Inhibitors 2-((1S)-1-((6-Amino-5-cyano-4-pyrimidinyl)amino)ethyl)-6-fluoro-N-methyl-3-(2-pyridinyl)-4-quinolinecarboxamide (AM-0687) and 2-((1S)-1-((6-Amino-5-cyano-4-pyrimidinyl)amino)ethyl)-5-fluoro-N-methyl-3-(2-pyridinyl)-4-quino

J. McCarter, D. Whittington, Iain D. G. Campuzano, 2016, Journal of medicinal chemistry.

An improved preparation of arylboronates: application in one-pot Suzuki biaryl synthesis.

Lei Zhu, Jason Duquette, Mingbao Zhang, 2003, The Journal of organic chemistry.

Design and optimization of imidazole derivatives as potent CXCR3 antagonists.

B. Lemon, S. Miao, T. Sullivan, 2008, Bioorganic & medicinal chemistry letters.

Discovery of AM-7209, a potent and selective 4-amidobenzoic acid inhibitor of the MDM2-p53 interaction.

Y. Wang, J. Canon, J. Oliner, 2014, Journal of medicinal chemistry.

A Scalable Asymmetric Synthesis of (R)-2-Amino-1-(3-pyridinyl)ethanol Dihydrochloride via an Oxazaborolidine Catalyzed Borane Reduction

Lei Zhu, Jason Duquette, Mingbao Zhang, 2003 .

Discovery of AMG 232, a potent, selective, and orally bioavailable MDM2-p53 inhibitor in clinical development.

Y. Wang, J. Canon, M. Peterson, 2014, Journal of medicinal chemistry.

Novel inhibitors of the MDM2-p53 interaction featuring hydrogen bond acceptors as carboxylic acid isosteres.

J. Canon, J. Oliner, Xin Huang, 2014, Journal of medicinal chemistry.

Discovery, Optimization, and in Vivo Evaluation of Benzimidazole Derivatives AM-8508 and AM-9635 as Potent and Selective PI3Kδ Inhibitors.

J. McCarter, D. Whittington, D. Metz, 2016, Journal of medicinal chemistry.

Optimization of the heterocyclic core of the quinazolinone-derived CXCR3 antagonists.

B. Lemon, T. Sullivan, G. Tonn, 2008, Bioorganic & medicinal chemistry letters.

Selective and potent morpholinone inhibitors of the MDM2-p53 protein-protein interaction.

J. Canon, J. Oliner, Xin Huang, 2014, Journal of medicinal chemistry.

Discovery and in vivo evaluation of (S)-N-(1-(7-fluoro-2-(pyridin-2-yl)quinolin-3-yl)ethyl)-9H-purin-6-amine (AMG319) and related PI3Kδ inhibitors for inflammation and autoimmune disease.

Xiaolin Hao, Ben Fisher, Andreas Reichelt, 2015, Journal of medicinal chemistry.

Discovery and optimization of a novel series of GPR142 agonists for the treatment of type 2 diabetes mellitus.

Ming Yu, Ryo Okuyama, J. Reagan, 2012, Bioorganic & medicinal chemistry letters.

Practical and Scaleable Syntheses of 3-Hydroxythiophenol

D. Ryckman, Guohua Chen, Jason Duquette, 2003 .

Imidazo-pyrazine derivatives as potent CXCR3 antagonists.

B. Lemon, Zhulun Wang, S. Miao, 2009, Bioorganic & medicinal chemistry letters.

Imidazo-pyrazine derivatives as potent CXCR3 antagonists.

B. Lemon, Zhulun Wang, S. Miao, 2009, Bioorganic & medicinal chemistry letters.

Discovery of AMG 925, a FLT3 and CDK4 dual kinase inhibitor with preferential affinity for the activated state of FLT3.

K. Pattabiraman, Zhulun Wang, C. Quéva, 2014, Journal of medicinal chemistry.